Theravance Bio Ord (TBPH) Stock Price, Quote & News

Company Profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a str...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 808 6000

Website: www.theravance.com

Address:

901 Gateway Boulevard, South San Francisco, United States

d_risk Aug. 14 at 5:00 AM

$TBPH - Theravance Biopharma Inc. Ordinary Shares - 10Q - Updated Risk Factors TBPH’s updated risks highlight exposure to healthcare law changes, US co-promotion hurdles with Viatris, expanded clinical trial and regulatory complexities, tax reform and transfer pricing scrutiny, internal controls, IP and product liability litigation, data protection, activist shareholder disruption, and anti-takeover defenses, while removing some prior YUPELRI and Cayman Islands risks. #HealthcareLaw #Anti-Takeover #ShareholderActivism #DataProtection #ProductLiability #IPLitigation #InternalControls #TransferPricing #TaxReform #RegulatoryComplexity #ClinicalTrials #Co-PromotionChallenges 🟢 Added 🟠 Removed https://d-risk.ai/TBPH/10-Q/2025-08-13

0 · Reply

ZacksResearch Aug. 13 at 5:17 PM

$TBPH beats expectations in Q2 📈 Loss came in narrower than expected with revenues up year over year, fueled by stronger Yupelri sales and licensing gains. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2707979/theravances-q2-loss-narrower-than-expected-revenues-rise-yy?cid=sm-stocktwits-2-2707979-teaser-7780&ADID=SYND_STOCKTWITS_TWEET_2_2707979_TEASER_7780

0 · Reply

ZacksResearch Aug. 13 at 4:06 PM

$TBPH Q2 earnings surprise! 📈 Theravance cut its loss to 8 cents per share, beating the Zacks Consensus Estimate of a 14-cent loss. Revenues surged by 83.2% year over year, owing to increased collaboration revenues from Viatris and licensing revenues. Year to date, TBPH shares have rallied 26.6%, outpacing the industry's 5.3% rise. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2707979/theravances-q2-loss-narrower-than-expected-revenues-rise-yy?cid=sm-stocktwits-2-2707979-body-7726&ADID=SYND_STOCKTWITS_TWEET_2_2707979_BODY_7726

0 · Reply

Doozio Aug. 9 at 2:00 PM

$TBPH wen?

0 · Reply

kshonstocks Aug. 8 at 5:26 PM

$TBPH looks gd

0 · Reply

NVDAMillionaire Jul. 29 at 9:36 PM

$TBPH Outstanding article that hits the mark on TBPH's current state. So if you want to refresh your TBPH insights or learn about TBPH from scratch, this is a must read. https://beyondspx.com/article/theravance-biopharma-unlocking-value-through-pipeline-catalysts-and-strategic-asset-management-tbph

0 · Reply

topstockalerts Jul. 4 at 5:39 PM

$TBPH where’s she going next?? ..🚨🚨..

0 · Reply

BioTechHealthX Jul. 4 at 5:30 PM

$TBPH This cash-rich, debt-free company is advancing a rare disease blockbuster while pulling in strong COPD revenue. Check Theravance Biopharma. https://biotechhealthx.com/biotech-news/biotech-bargain-alert-theravance-biopharma-tbph-may-offer-triple-digit-upside-in-2025/

0 · Reply

Doozio Jul. 4 at 4:36 PM

$TBPH faatch 💣 or 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jul. 4 at 4:35 PM

$TBPH mmmkay whuteva bruh. 2025 is 6/2/25 gap n GOGOs during 🐒🍌🧠⏰♾️

0 · Reply

Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 10 days ago

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 28, 2025, 6:00 AM EDT - 25 days ago

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 23, 2025, 6:00 AM EDT - 4 weeks ago

Theravance Biopharma to Participate in an Upcoming Investor Conference

Jun 26, 2025, 6:00 AM EDT - 2 months ago

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

Jun 2, 2025, 6:00 AM EDT - 2 months ago

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

GSK

May 10, 2025, 4:35 PM EDT - 3 months ago

Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript

May 9, 2025, 12:00 PM EDT - 3 months ago

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

May 8, 2025, 4:05 PM EDT - 3 months ago

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 6:00 AM EDT - 4 months ago

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

Apr 24, 2025, 6:00 AM EDT - 4 months ago

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 7, 2025, 3:55 PM EDT - 4 months ago

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

Mar 27, 2025, 6:00 AM EDT - 5 months ago

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Feb 26, 2025, 8:58 PM EST - 6 months ago

Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 6 months ago

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 6:00 AM EST - 6 months ago

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Dec 17, 2024, 6:00 AM EST - 8 months ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Nov 12, 2024, 10:46 PM EST - 10 months ago

Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 10 months ago

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Oct 24, 2024, 6:00 AM EDT - 10 months ago

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

Oct 18, 2024, 9:00 AM EDT - 11 months ago

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease

Aug 5, 2024, 7:37 PM EDT - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:05 PM EDT - 1 year ago

Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024

May 13, 2024, 6:58 PM EDT - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:05 PM EDT - 1 year ago

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 29, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

Apr 10, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

Feb 26, 2024, 9:52 PM EST - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:05 PM EST - 1 year ago

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 14, 2024, 6:00 AM EST - 1 year ago

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Jan 5, 2024, 6:15 AM EST - 1 year ago

Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal

Jan 5, 2024, 6:00 AM EST - 1 year ago

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Dec 21, 2023, 5:00 PM EST - 1 year ago

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

Dec 18, 2023, 6:00 AM EST - 1 year ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference

Nov 16, 2023, 6:00 AM EST - 1 year ago

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

Nov 15, 2023, 6:00 AM EST - 1 year ago

Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 8:00 AM EST - 1 year ago

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

VTRS

Nov 7, 2023, 11:23 PM EST - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:28 PM EST - 1 year ago

Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 19, 2023, 6:00 AM EDT - 2 years ago

Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023

Sep 9, 2023, 11:49 AM EDT - 2 years ago

Theravance: Positive Findings Boost Ampreloxetine Development

Sep 8, 2023, 10:12 AM EDT - 2 years ago

Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold

Aug 28, 2023, 6:06 AM EDT - 2 years ago

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

Aug 7, 2023, 9:33 PM EDT - 2 years ago

Theravance Biopharma, Inc. (TBPH) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 4:05 PM EDT - 2 years ago

Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023

May 9, 2023, 6:00 PM EDT - 2 years ago

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

May 8, 2023, 10:39 PM EDT - 2 years ago

Theravance Biopharma, Inc. (TBPH) Q1 2023 Earnings Call Transcript

May 8, 2023, 4:05 PM EDT - 2 years ago

Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

d_risk Aug. 14 at 5:00 AM

0 · Reply

ZacksResearch Aug. 13 at 5:17 PM

0 · Reply

ZacksResearch Aug. 13 at 4:06 PM

0 · Reply

Doozio Aug. 9 at 2:00 PM

$TBPH wen?

0 · Reply

kshonstocks Aug. 8 at 5:26 PM

$TBPH looks gd

0 · Reply

NVDAMillionaire Jul. 29 at 9:36 PM

0 · Reply

topstockalerts Jul. 4 at 5:39 PM

$TBPH where’s she going next?? ..🚨🚨..

0 · Reply

BioTechHealthX Jul. 4 at 5:30 PM

0 · Reply

Doozio Jul. 4 at 4:36 PM

$TBPH faatch 💣 or 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jul. 4 at 4:35 PM

$TBPH mmmkay whuteva bruh. 2025 is 6/2/25 gap n GOGOs during 🐒🍌🧠⏰♾️

0 · Reply

JarvisFlow Jun. 27 at 3:00 PM

BTIG updates rating for Theravance Biopharma ( $TBPH ) to Buy, target set at 24 → 25.

0 · Reply

BioTuesdays Jun. 26 at 4:00 PM

Theravance Biopharma has announced that China’s National Medical Products Administration (NMPA) has granted regulatory approval for YUPELRI, the company’s revefenacin inhalation solution for the treatment of chronic obstructive pulmonary disease (COPD) $TBPH https://biotuesdays.com/2025/06/26/nmpa-approves-theravances-yupelri-for-copd-in-china/

0 · Reply

OpenOutcrier Jun. 26 at 12:22 PM

$TBPH (+4.9% pre) Theravance Biopharma (TBPH) Gains From Yupelri Approval in China https://ooc.bz/l/68775

0 · Reply

DonCorleone77 Jun. 26 at 10:32 AM

$TBPH $VTRS Theravance Biopharma announces Viatris approval for Yupelri in China Theravance Biopharma (TBPH) announced that Viatris (VTRS), has secured regulatory approval from China's National Medical Products Administration for Yupelri inhalation solution, the first once-daily nebulized long-acting muscarinic antagonist approved for maintenance treatment of chronic obstructive pulmonary disease in China. This approval triggers a one-time $7.5M from Viatris to Theravance Biopharma, which is expected to be received in Q3. Theravance Biopharma is also eligible for further sales-based milestones of up to $37.5M and tiered royalties of 14% to 20% on net sales in China. Viatris is responsible for all aspects of development and commercialization of Yupelri in China.

0 · Reply

mebanks Jun. 26 at 10:13 AM

$TBPH full of cash, "Theravance Biopharma (NASDAQ:TBPH) announced that its partner Viatris has received approval from China's NMPA for YUPELRI® (revefenacin), the first once-daily nebulized LAMA for COPD maintenance treatment in China. The approval triggers a $7.5 million milestone payment to TBPH, with potential for additional sales-based milestones up to $37.5 million and tiered royalties of 14% to 20% on net sales in China. Viatris will handle all commercialization aspects. TBPH's financial position includes $131 million in cash, $225 million from TRELEGY royalties sale to GSK, 35% of U.S. YUPELRI profits, and up to $150 million in potential TRELEGY milestone payments." https://www.stocktitan.net/news/TBPH/theravance-biopharma-announces-approval-of-yupelri-revefenacin-by-93dupui8ifq3.html

0 · Reply

JarvisFlow Jun. 17 at 11:30 AM

Jones Trading updates rating for Theravance Biopharma ( $TBPH ) to Buy, target set at 24.

0 · Reply

ZacksResearch Jun. 3 at 4:41 PM

$TBPH pops 22% on $225M royalty sale to GSK 🔥 Theravance is offloading its last chunk of Trelegy royalties — locking in major cash as part of the deal. What this means for the future of TBPH 👉 https://www.zacks.com/stock/news/2483631/tbph-to-sell-remaining-trelegy-royalty-interest-to-gsk-stock-rises?cid=sm-stocktwits-2-2483631-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2483631_TEASER

0 · Reply

ZacksResearch Jun. 3 at 3:08 PM

$TBPH surges 22% on royalty sale! 🚀💰 Theravance announced a $225 million cash deal with $GSK for its remaining royalty interest in Trelegy Ellipta, plus potential $150 million milestone payments. This rally follows the stock's 18.5% YTD performance against industry decline. Full details here 👉 https://www.zacks.com/commentary/2483631/tbph-to-sell-remaining-trelegy-royalty-interest-to-gsk-stock-rises?cid=sm-stocktwits-2-2483631-body&ADID=SYND_STOCKTWITS_TWEET_2_2483631_BODY

0 · Reply

PenkeTrading Jun. 3 at 1:30 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Theravance Biopharma Inc. Is that bullish or bearish? $TBPH #RsiOverbought #NASDAQ

0 · Reply

GSP Jun. 3 at 1:11 PM

$TBPH $MODV $UMAC $APLD $UAVS

0 · Reply

BearTamerTrading Jun. 2 at 8:51 PM

Profit Secured🔒💰🔒 If you tuned into my live YouTube trading session this morning and/or you are a member of the discord “Capital Conspiracy Trading” you would have received our alert🚨before this play took off. Subscribe to my channel on YouTube so you don’t miss out. Also consider our discord group for an even higher earning potential. Thank you for the love & support on Webull & Stocktwits. https://www.youtube.com/live/AwEXxMilFAQ?si=coS54X8d5DiFfbr_ $BMGL $NIVF $TBPH $INM $RVYL

1 · Reply

mebanks Jun. 2 at 10:23 AM

$TBPH saying that cash is king, lets see how the market reacts (Shs Float 45.85M based on Finviz)

0 · Reply

Market Cap	687.93M
Revenue (ttm)	64.38M
Net Income (ttm)	-56.42M
EPS (ttm)	N/A
PE Ratio	55.79
Forward PE	N/A
Profit Margin	-87.64%
Debt to Equity Ratio	0.00

Volume	846,000
Avg Vol	290,924
Day's Range	N/A - N/A
Shares Out	50.36M
Stochastic %K	87%
Beta	0.01
Analysts	Strong Sell
Price Target	$18.40